Horizon Discovery has announced the formation of Avvinity Therapeutics, a JV with Centauri Therapeutics, to pursue joint discovery and pre-clinical development of novel oncology therapies. The initiative represents a continuation of Horizon’s Leveraged R&D strategy, which aims to maximise the return potential for the company’s leading gene editing and cell line expertise. We retain a Buy recommendation and 194p target price.
